| 1 |
35348191 | Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells. | 2022 May |
1 |
| 2 |
35511749 | A high-throughput screening platform identifies novel combination treatments for Malignant Peripheral Nerve Sheath Tumors. | 2022 May 5 |
1 |
| 3 |
35619328 | Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer. | 2022 May 26 |
2 |
| 4 |
33672646 | Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling. | 2021 Feb 20 |
1 |
| 5 |
33869031 | WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. | 2021 |
1 |
| 6 |
34212455 | Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer. | 2021 Sep |
4 |
| 7 |
32611648 | A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. | 2020 Sep 15 |
3 |
| 8 |
30679201 | Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition. | 2019 May |
3 |
| 9 |
30943845 | p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775. | 2019 Apr |
1 |
| 10 |
29783721 | AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations. | 2018 May 19 |
3 |
| 11 |
30403169 | Gastric carcinoma with a gastrointestinal stromal tumor - A case report and literature review. | 2018 Oct |
1 |
| 12 |
28296564 | AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells. | 2017 |
3 |
| 13 |
28790110 | Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation. | 2017 Nov 1 |
1 |
| 14 |
28927115 | WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. | 2017 Sep |
1 |
| 15 |
26975930 | Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. | 2016 Jun 1 |
1 |
| 16 |
27077811 | Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy. | 2016 Apr 14 |
2 |
| 17 |
27998224 | Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. | 2016 Dec 20 |
1 |
| 18 |
25283841 | A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. | 2015 Apr |
2 |
| 19 |
25504633 | Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. | 2015 Feb |
8 |
| 20 |
24885658 | Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies. | 2014 May 22 |
2 |
| 21 |
23520471 | Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. | 2013 |
1 |
| 22 |
22084170 | MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. | 2012 Jan |
1 |
| 23 |
21799033 | MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. | 2011 Sep 1 |
6 |
| 24 |
20107315 | MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. | 2010 Apr 1 |
2 |
| 25 |
19887545 | Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. | 2009 Nov |
2 |